We have further demonstrated that NFAT1 and NFAT1-MDM2 pathway play a critical role in JapA's inhibitory effects against human cancer, as indicated in NFAT1 OE and KD MCF-7 (p53 wild-type) and MDA-MB-231 (p53 mutant) breast cancer cell lines. This evidence concerns the gene TP53 and breast carcinoma.